Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Surgery
Published in: European Surgery 3/2020

01-06-2020 | Metastasis | review

The real risk of nodal disease in T1 oesophageal adenocarcinoma

A systematic review

Authors: David P. Mitchell, BSc MBBS FRACS, Sashi Yeluri, MBBS FRCS, Hans Van der Wall, PhD, FRACP, Gregory L. Falk, MBBS FRCS FRACS

Published in: European Surgery | Issue 3/2020

Login to get access

Summary

Background

Lymph node status is regarded as an important factor in the prognosis of oesophageal cancer. T1 oesophageal adenocarcinoma management has to include endoscopic management as part of the algorithm. We reviewed the literature to assess the true risk of lymph node metastasis in patients with T1 oesophageal adenocarcinoma.

Methods

Medline, Embase, PubMed and Cochrane where searched for manuscripts in English reviewing lymph node metastasis in superficial (T1) oesophageal adenocarcinoma. The main outcome was probability of lymph node metastasis in T1a and T1b oesophageal adenocarcinoma. Secondary outcome was the rate of lymph node metastasis of submucosal involvement of T1b (SM1, SM2 and SM3).

Results

There were 38 studies identified. 22 studies were excluded due to low lymph node yield (<15) or insufficient statistical analysis. For the 16 remaining studies, a total of 1382 cases were included: T1a adenocarcinoma (533 patients) with 11 (2%) node positive and T1b adenocarcinoma (849 patients) with 189 (22%) node positive. Subgroup analysis of T1b lesions was available in 8 reports (365 patients). Node positivity for SM1, SM2 and SM3 was 19.9%, 20.2% and 32.9%, respectively.

Conclusion

T1a disease on endoscopic mucosal resection (EMR) demonstrates a 2% nodal metastasis rate, T1b disease a rate of 22%. T1a disease may be safely treated by EMR. T1a disease appears suitable for endoscopic therapy; however, T1b disease presents a high rate of nodal metastasis.
Literature
1.
Ajani JA, et al. Esophageal and Esophagogastric Junction Cancers, version2.2019, NCCNClinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–883PubMed
2.
Chadwick G, Varagunam M, Brand C, et al. National Oesophag-Gastric Cancer Audit. An Audit of the care received by people with Oesophago-Gastric Cancer in England and Wales. Ninth Annual Report 2016. L.N.I. Centre; 2016.
3.
Nobel T, et al. Ongoing challenges with clinical assessment of nodal status in T1 esophageal adenocarcinoma. J Am Coll Surg. 2018;229(4):366–73.
4.
van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMed
5.
Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMed
6.
Gockel I, et al. Prediction model of lymph node metastasis in superficial esophageal adenocarcinoma and squamous cell cancer including D2-40 immunostaining. J Surg Oncol. 2009;100(3):191–8.PubMed
7.
Stein HJ, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg. 2005;242(4):566–73. discussion 573–575.PubMedPubMedCentral
8.
Holscher AH, et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg. 2011;254(5):802–7. discussion 807–808.PubMed
9.
Sepesi B, et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg. 2010;210(4):418–27.PubMed
10.
Nigro JJ, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg. 1999;117(1):16–23. discussion 23–25.PubMed
11.
Griffin SM, Burt AD, Jennings NA. Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg. 2011;254(5):731–6. discussion 736–737.PubMed
12.
Badreddine RJ, Prasad G, Lewis JT, Lutzke LS, Borkenhagen LS, Dunagan KT, et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol. 2010;8(3):248–53.PubMed
13.
Manner H, et al. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc. 2015;29(7):1888–96.PubMed
14.
Leers JM, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg. 2011;253(2):271–8.PubMed
15.
Gertler R, et al. Prevalence and topography of lymph node metastases in early esophageal and gastric cancer. Ann Surg. 2014;259(1):96–101.PubMed
16.
Lee L, et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg. 2013;217(2):191–9.PubMed
17.
Nentwich MF, et al. Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus. J Gastrointest Surg. 2014;18(2):242–9. discussion 249.PubMed
18.
Bogoevski D, et al. How radical should surgery be for early esophageal cancer? World J Surg. 2011;35(6):1311–20.PubMed
19.
Hagen JA, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234(4):520–30. discussion 530–531.PubMedPubMedCentral
20.
Molena D, et al. Esophagectomy following endoscopic resection of submucosal esophageal cancer: a highly curative procedure even with nodal metastases. J Gastrointest Surg. 2017;21(1):62–7.PubMed
21.
Bollschweiler E, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy. 2006;38(2):149–56.PubMed
22.
Samson P, et al. Adhering to quality measures in esophagectomy is associated with improved survival in all stages of esophageal cancer. Ann Thorac Surg. 2017;103(4):1101–8.PubMedPubMedCentral
23.
Altorki NK, et al. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg. 2008;247(3):434–9.PubMed
24.
Greenstein AJ, et al. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg. 2008;206(2):239–46.PubMed
25.
Peyre CG, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549–56.PubMed
26.
Rizk NP, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.PubMed
27.
Rösch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am. 1995;5(3):537–47.PubMed
28.
Sandha GS, et al. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography, and EUS. Gastrointest Endosc. 2008;67(3):402–9.PubMed
29.
Cuellar SL, et al. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014;9(8):1202–6.PubMed
30.
van Vliet EP, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547–57.PubMedPubMedCentral
31.
Ell C, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc. 2007;65(1):3–10.PubMed
32.
Pech O, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014;146(3):652–660e1.PubMed
33.
Manner H, et al. Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol. 2009;104(3):566–73.PubMed
34.
Collard JM. High-grade dysplasia in Barrett’s esophagus. The case for esophagectomy. Chest Surg Clin N Am. 2002;12(1):77–92.PubMed
35.
Van Vilsteren FG, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011;60(6):765–73.PubMed
36.
Phoa KN, et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut. 2016;65(4):555–62.PubMed
37.
Orman ES, et al. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(10):1245–55.PubMed
38.
The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach and colon. GastroIntest Endo. 2003;58(6Suppl):S3-43
39.
Weusten B, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:2589–97.
40.
Manner H, et al. Early Barrett’s carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103(10):2589–97.PubMed
41.
Alvarez Herrero L, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy. 2010;42(12):1030–6.PubMed
42.
43.
Ancona E, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15(11):3278–88.PubMed
44.
Wani S, et al. Comparison of endoscopic therapies and surgical resection in patients with oesophageal cancer: a population-based study. Gastrointest Endosc. 2014;79(2):224–32.PubMed
45.
Pennathur A, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009;87(4):1048–54. discussion 1054–1055.PubMedPubMedCentral
46.
Rice TW, et al. 8th edition AJCC/UICC staging of cancers of the esophahstric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.PubMedPubMedCentral
Metadata
Title
The real risk of nodal disease in T1 oesophageal adenocarcinoma
A systematic review
Authors
David P. Mitchell, BSc MBBS FRACS
Sashi Yeluri, MBBS FRCS
Hans Van der Wall, PhD, FRACP
Gregory L. Falk, MBBS FRCS FRACS
Publication date
01-06-2020
Publisher
Springer Vienna
Published in
European Surgery / Issue 3/2020
Print ISSN: 1682-8631
Electronic ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-019-00627-x

Other articles of this Issue 3/2020

European Surgery 3/2020 Go to the issue

editorial

Surgery watch out the needle eye

original article

How effective is the control of laryngopharyngeal reflux symptoms by fundoplication? Symptom score analysis

original article

Misdiagnosis of cystic pancreatic tumors during a 30-year study period

original article

Combined pharmacologic antireflux therapy after esophagectomy: effect on symptoms and endoscopic findings at 1-year follow-up

original article

Does giving pasireotide to patients undergoing pancreaticoduodenectomy always pay for itself?

review

Breast reconstruction with the omentum flap: a case report with unsatisfactory outcome and review of the literature